The global intragastric balloons market size is expected to reach USD 100.2 million by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.9% from 2021 to 2028. The rise in obesity and increasing demand for minimally invasive procedures are anticipated to be key market drivers.
Intragastric balloons are one of the most widely adopted endoscopic bariatric therapy devices in clinical settings. This can be attributed to complications associated with surgical weight loss treatments and the low eligibility criteria for surgical options leading to a rise in demand for effective minimally invasive weight-loss treatment options.
The safety concerns associated with the inflatable medical device are anticipated to make the pre-market and post-market scrutiny process of these devices by the regulatory authorities more stringent. For instance, in 2019, Apollo Endosurgery Inc., revised the labeling of its Orbera Intragastric Balloon System to include contradiction clarifications, precautions related to anticholinergic and psychotropic medications, and updated U.S. adverse event tables after it received an FDA safety letter.
Nonetheless, the extensive research activities related development of innovative and novel systems and up-gradation of existing intragastric balloons to overcome the shortcomings of the traditional inflatable medical devices are anticipated to facilitate market growth.
Request a free sample copy or view report summary: Intragastric Balloons Market Report
According to The American Society for Metabolic and Bariatric Surgery (ASMBS) data, nearly 5,000 intragastric balloon implantations have been conducted since their U.S. FDA approval
The single segment held the largest revenue share of the market in 2020 while the triple segment is expected to grow at a fast pace
The gas-filled segment is anticipated to witness lucrative growth over the forecast period
The hospital segment held significant revenue share in 2020 while the ambulatory surgical centers segment is expected to grow at a rapid pace
The endoscopy segment dominated the market in 2020 and the pill form segment is expected to witness lucrative growth over the forecast period
North America dominated the market in 2020 due to the presence of a large obese population and high adoption of bariatric procedures. In Asia Pacific, the market is expected to witness remunerative growth over the forecast period
As of January 2019, Apollo Endosurgery has discontinued the sales and distribution of its ReShape Balloon
Grand View Research has segmented the intragastric balloons market on the basis of administration, balloon type, filling material, end use, and region:
Intragastric Balloons Administration Outlook (Revenue, USD Million, 2016 - 2028)
Pill Form
Endoscopy
Intragastric Balloons Type Outlook (Revenue, USD Million, 2016 - 2028)
Single
Dual
Triple
Intragastric Balloons Filling Material Outlook (Revenue, USD Million, 2016 - 2028)
Saline Filled
Gas Filled
Intragastric Balloons End-use Outlook (Revenue, USD Million, 2016 - 2028)
Hospitals
Clinics
Ambulatory surgical centers
Intragastric Balloons Regional Outlook (Revenue, USD Million, 2016 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
The Netherlands
Belgium
Switzerland
Turkey
Poland
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Indonesia
Malaysia
Philippines
Singapore
Latin America
Brazil
Mexico
Argentina
Chile
Colombia
MEA
South Africa
Saudi Arabia
UAE
Israel
Egypt
List of Key Players of Intragastric Balloons Market
Apollo Endosurgery, Inc.
Obalon Therapeutics, Inc.
Allurion Technologies, Inc.
Spatz3
Helioscopie
Endalis
MEDSIL
ReShape Medical, Inc.
Lexel Medical
"The quality of research they have done for us has been excellent..."